To evaluate the clinical benefit of extended endocrine therapy after 5 years of adjuvant treatment with LHRHa in premenopausal women with node-positive, HR-positive early breast cancer.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Sara M. Tolaney, ...

And so we really need more research into how to optimize these patients long-term, especially when we generally do not use menopausal hormone therapy in hormone receptor positive breast cancer.

Positive Development, a developmental therapy provider for children with autism, announced Wednesday that it raised $51.5 million in Series C funding. The McLean, Virginia-based company’s model is ...

The evolution of treatments for human epidermal growth factor receptor 2 (HER2)–positive breast cancer offers one of the most compelling success stories in contemporary oncology. The advent of ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted ...

—Building on earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer, plus identify factors ...